The first bispecific Notch antibody nearing approval is the anti-vascular endothelial growth factor (VEGF)/DLL4 IgG2 navicixizumab, which in late 2019 was granted fast-track designation for FDA-approval in pretreated ovarian cancer (https://www.targetedonc.com/view/fda-fast-track-designation-granted-to-navicixizumab-for-heavily-pretreated-ovarian-cancer). This evidence concerns the gene VEGFA and ovarian carcinoma.